Yipinhong Reports Positive China Phase III Results for Gout Drug AR882

On September 15, 2026, Yipinhong (300723) held its 2026 interim results briefing. Chairman and general manager Li Hanxiong presented progress on the company's investigational gout drug AR882. Li said AR882 has been tested in a China Phase III trial in participants with gout and hyperuricemia, that the company has obtained the trial results, and that it will communicate with drug regulators to advance a marketing application.

AR882 is a next-generation highly selective urate transporter 1 (URAT1) inhibitor. By inhibiting uric acid reabsorption, it promotes renal excretion of urinary urate and thereby lowers serum uric acid (sUA) levels for the treatment of gout and tophi. The drug binds durably to the urate transporter, and clinical results show its efficacy lasts up to 24 hours. The company disclosed that AR882 can block uric acid reabsorption around the clock and clear uric acid from the body.

Regarding exploratory tophus-related endpoints, Li said data on AR882 have accumulated progressively across clinical stages. Published global Phase II results showed that after six months of dosing, 29% of subjects in the 75mg dose group had at least one target tophus completely resolved, with dual-energy CT (DECT) imaging concurrently recording a reduction in total urate crystal volume. After 12 months of dosing, among the subgroup of subjects with an inadequate response to prior urate-lowering therapy, 43% of those in the monotherapy group achieved complete resolution of at least one target tophus. Li said subsequent global Phase III studies will systematically validate prespecified exploratory endpoints, including tophus dissolution.